Helen Van Miegroet

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

Els Lierman, Cedric Folens, Elizabeth H. Stover et al. · Blood · 2006 · 132 citations · Full text

The ability of sorafenib to inhibit oncogenic PDGFR  and FLT3 mutants and overcome resistance to other small molecule inhibitors

Els Lierman, Idoya Lahortiga, Helen Van Miegroet et al. · Haematologica · 2007 · 93 citations · Full text

<i>APP</i>and<i>BACE1</i>miRNA genetic variability has no major role in risk for Alzheimer disease

Karolien Bettens, Nathalie Brouwers, Sebastiaan Engelborghs et al. · Human Mutation · 2009 · 52 citations

Genetics, Genetic Epidemiology, Amyloid Precursor Protein +21

Common variation in<i>GRB-associated Binding Protein 2 (GAB2)</i>and increased risk for Alzheimer dementia

Kristel Sleegers, Karolien Bettens, Nathalie Brouwers et al. · Human Mutation · 2008 · 36 citations · Full text

Follow-Up Study of Susceptibility Loci for Alzheimer's Disease and Onset Age Identified by Genome-Wide Association

Karolien Bettens, Nathalie Brouwers, Helen Van Miegroet et al. · Journal of Alzheimer s Disease · 2010 · 35 citations · Full text